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The development of cancer is driven by complex genetic and epigenetic changes that
result in aberrant and uncontrolled cellular growth. Epigenetic changes, in particular, are
implicated in the silencing or activation of key genes that control cellular growth and
apoptosis and contribute to transformative potential. The purpose of this review is to
define and assess the treatment strategy of “episensitization,” or the ability to sensitize
cancer cells to subsequent therapy by resetting the epigenetic infrastructure of the tumor.
One important facet is resensitization by epigenetic mechanisms, which goes against the
norm, i.e., challenges the long-held doctrine in oncology that the reuse of previously
tried and failed therapies is a clinically pointless endeavor. Thus, episensitization is
a hybrid term, which covers recent clinically relevant observations and refers to the
epigenomic mechanism of resensitization. Among the many formidable challenges in
the treatment of cancer, the most inevitable is the development of acquired therapeutic
resistance. Here, we present the basic principles behind episensitization and highlight
the evidence suggesting that epigenetically mediated histone hypoacetylation and DNA
hypermethylation events may reverse clinical drug resistance. The potential reversibility
of epigenetic changes and the microenvironmental impact of epigenetic control on
gene expression may mediate a return to a baseline state of treatment susceptibility.
Episensitization is a novel and highly practical management strategy both to prevent
the practice of permanent treatment discontinuation with the occurrence of resistance,
which rapidly exhausts remaining options in the pharmaceutical armamentarium and to
significantly extend patient survival. Accordingly, this review highlights several epigenetic
agents including decitabine, vorinostat, entinostat, 5-azacitidine, oncolytic viruses, and
RRx-001.
Keywords: episensitization, epigenetics, epigenomic, resensitization, RRx-001, oncology
Abbreviations: ATP, adenosine triphosphate; AZA, azacitidine; BOND, bowel oncology and cetuximab antibody; CEA,
carcinoembryonic antigen; CT, computer tomography; DAC, decitabine; DNMT, DNA methyltransferase; EGFR, epidermal
growth factor receptor; FDA, US food and drug Administration; GI, gastrointestinal; GU, genitourinary; HCC, hepatocellular
carcinoma; HDAC, histone deacetylase; MTD, maximally tolerated dose; mCRC, metastatic colorectal cancer; NSCLC, non-
small cell lung cancer; OS, overall survival; PET, positron emission tomography; PR, partial response; ROCKET, RRx-
001 in colon cancer taken to extend time; SD, stable disease; TKIs, tyrosine kinase inhibitors; VEGF, vascular endothelial
growth factor.
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Introduction
The purpose of this review is to define and critically appraise
the treatment strategy of “episensitization” or resensitization by
epigenetic means, which challenges the long-standing, largely
implicit tradition in oncology that the reuse of previously tried
therapies constitutes a risky business with little real benefit to
the patient. Unsurprisingly, given this implicit stigma, the lit-
erature about resensitization is limited. Nevertheless, over the
years, several sources have provided a somewhat vague definition
of resensitization1, with a lack of appositive context clues or
morphemic analysis, as “A second or subsequent sensitization,
especially following desensitization.” In an attempt to avoid confu-
sion, we define resensitization as follows: “the renewal of clinical
benefit from chemotherapy, immunotherapy, or radiotherapy that
was previously effective but to which the tumor had become
desensitized or resistant.” This definition has several important
and potentially controversial consequences. One is that episen-
sitization has the potential to reverse the direction of molecular
entropy (since the micro-morphological andmolecular landscape
of cancer is defined by maximum entropy) and thereby defy
time’s arrow. Episensitization is a neologism, coined by Oronsky,
Scicinski, Fanger, and Reid, which covers recent clinically rele-
vant observations and refers to the epigenomic mechanism for
resensitization (1).
The complexity of cancer, which includes tumor heterogeneity,
the lack of specific actionable targets, a mercurial microenviron-
ment, and immunosuppression, makes it an extremely challeng-
ing disease to treat; and any clinical benefit from treatment is
often tempered by the inevitable development of acquired ther-
apeutic resistance and tumor progression (2, 3). Progression is a
particularly apt term to describe the discrete, forward marching
sequence of treatment steps as resistance develops and the disease
worsens over time. The apparent reversibility of resistance by
episensitization has the potential to run the arrow of time back-
wards, replacing progression with regression. This one-way arrow
of temporality defines entropy, a thermodynamic expression of
increasing disorder over time that has been repeatedly applied to
and closely associated with the features of cancer tissue or cells.
According to the Second Law of Thermodynamics, natural
processes tend to move from ordered to disordered states. For
example, the dissolution of sugar cubes in coffee or the disper-
sion of perfume molecules in the air is irreversible processes,
which from experience never proceed in the opposite direction:
nomatter how long the interval, neither the sugar nor the perfume
molecules will spontaneously reverse their trajectories and reform
as cubes or reassemble in the bottle, respectively. In other words,
what is done cannot be undone, time moves in one direction and
one direction only, forward not backwards, irreversibly.
Similarly, over time and after treatment, cancer cells tend
to become more resistant to therapy. In this way, the one-way
arrow of temporality points toward inevitable treatment failure
as cancer patients traverse multiple lines of therapy in a more or
less linear sequence, first-line, second-line, third-line etc., until
the only remaining option is hospice or a clinical trial. This
review presents the clinical evidence for episensitization, i.e., the
1http://en.wiktionary.org/wiki/resensitization. Accessed December 2014
reversal of drug resistance with the restitution of clinical activity
in terms of epigenetic gene reactivation mediated by histone
hypoacetylation and DNA hypermethylation. Accordingly, clin-
ical trials with several potential reset-button-pushing epigenetic
agents are highlighted in this review. These epigenetic agents are
decitabine (DAC), 5-azacitidine (AZA), entinostat, resminostat,
and RRx-001.
Worldwide, cancer is a leading cause of mortality (4) and resis-
tance to therapy, whether de novo or acquired, is a chief culprit.
Episensitization is a highly practical management strategy both as
an antidote to the practice of permanent discontinuation of treat-
ments at each line of therapy with the occurrence of resistance,
which rapidly exhausts remaining options in the pharmaceutical
armamentarium and as a blueprint to significantly extend patient
survival.
Keywords Defined
“Epigenetics” possesses several context-dependent definitions (5).
As the “next big thing” in oncology, epigenetics is an eminently
flexible concept that accommodates a range ofmeanings including
phenotypic plasticity and adaptive capacity. However, in the con-
text of this review, epigenetics refers to reversible changes in gene
expression, requiring activemaintenance (6) (unlike geneticmod-
ifications) and potentially manipulatable by small molecule DNA
methyltransferase (DNMT) and histone deacetylase (HDAC)
inhibitors. Epigenetic perturbations lead to alterations in gene
expression, which may drive malignant transformation and con-
tribute to the development of resistance to anti-cancer therapies
(7). According to Brown et al., “the high rate of epigenetic change
in tumors generates diversity in gene expression patterns that can
rapidly evolve through drug selection during treatment, leading to
the development of acquired resistance” (8).
For the purposes of this review, “resensitization” refers to clin-
ically meaningful benefit in the context of previous exposure to a
previously effective but now refractory medication while “sensiti-
zation” indicates improved clinical benefit in the absence of previ-
ous drug exposure. Episensitization is a blend word of epigenetics
and sensitization coined by Oronsky, Scicinski, Fanger, and Reid
that refers to the reversal of epigenetic changes associated with
resistance to treatment (9). An episensitization-related keyword is
“priming,” which refers to increased drug sensitivity, presumably
due to altered gene expression. In this context, epigenetic agents
“prime the pump” or reprogram the tumor so that it is poised
to respond to further treatment. A “primed” state may be short-
lived or longer-term (see the multi-epigenetic agent, RRx-001).
Epi-resensitization is a sub-category under the general rubric of
episensitization.
This review serves as an introduction to the relatively under-
explored strategy of tumor resensitization. Definitions, implica-
tions, and future directions are discussed.
Cancer Ecology
Cancer has been described (10) as an ecological process
whereby tumor cells reengineer and reorganize their environ-
ment, imposing significant physiologic stress (11), in order to
effectively out-compete the indigenous populations of normal
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cells in specific biological niches. The tumor effects a “chaotic”
rearrangement (12) that is characterized by specialized adverse
hallmark traits, e.g., hypoxia, nutrient deprivation, poor blood
flow, low pH, and increased oxidative stress and provides a favor-
able microenvironment for tumor cells relative to normal tissue.
Further, effective anti-cancer therapies may accentuate oncogenic
epigenetic reorganization, paradoxically leading to the increased
development of aggressive, drug-resistant tumor phenotypes.
The principle of “ecogenetic feedback” in evolutionary biol-
ogy (13) describes a synergistic interplay between ecological and
genetic effects. In a similar way, cancer cells dynamically regulate
transcription to match phenotype with the prevailing microen-
vironment. Thus, tumor cells epigenetically upregulate and
downregulate the expression of particular genes (14) in real-time,
resulting in reprograming-associated epigenetic/transcriptional
signatures (15). The collective behavior of these specific interac-
tions of gene and protein expression patterns is to optimize fitness
of the tumor cells in particular microenvironmental conditions.
This adaptive flexible responsiveness is known as phenotypic plas-
ticity (16) and greatly increases the competitiveness of the cancer
cell relative to non-neoplastic cells, allowing the tumor to adjust
its phenotype to the local microenvironment, provided that the
costs of an adaptive plastic response are not selectively prohibitive,
since the process of protein synthesis is energetically expensive
(17). An example of this is the repression of oxidative metabolism
that occurs in the presence of aerobic glycolysis (the Warburg
effect) (18), ametabolic hallmark of cancer cells, whereby requisite
ATP (adenosine triphosphate) is produced via increased glycolytic
flux. Cancer cells adapt to carefully adhere to an energy budget –
glycolysis is an inefficient process for ATP production, the net
yield of ATP per molecule of glucose degraded under anaerobic
conditions, 2 ATP, is far inferior to complete oxidation of one
glucose molecule by oxidative phosphorylation, which generates
up to 36–38 ATP molecules (19); hence, excess capacity is not
unlimited.
Treatment of cancerwithmolecularly targeted agents thatmod-
ulate specific genetic abnormalities like VEGF (vascular endothe-
lial growth factor), EGFR (epidermal growth factor receptor), or
BRAF has met with limited success because their specificity is
too narrow: the built-in phenotypic plasticity or flexibility (20,
21) of the cancer epigenome facilitates rapid and recurrent com-
pensatory adaptation, and the energetic costs that may constrain
adaptation are evidently not prohibitively expensive. Despite ini-
tial benefit of the treatment, tumor progression inevitably ensues
(22), due to the emergence of resistance through altered drug
metabolism, active drug export, modified expression or function
of the drug target, or through the activation of a downstream
molecule, all of which are risk factors for aggressive tumor behav-
ior and shortened overall patient survival.
Like molecularly targeted agents, epigenetic compounds “act”
locally and selectively on specific enzymes. But, unlike molec-
ularly targeted agents, epigenetic compounds “behave” globally,
pleiotropically affecting the expression of multiple genes, which
disrupts the complex interplay between multiple interacting and
interdependent cellular and microenvironmental elements, con-
sequently reducing tumor fitness. Through a relatively small per-
turbation, the inhibition of epigenetic modulators like HDACs or
DNMT, the pattern of coordinated gene expression in the tumor
is altered, resulting in a multiplier effect (23). For example, while
inhibition of HDAC activity affects the expression of only 5–20%
of protein-coding genes (24), the fact that these proteins converge
on pathways governing gene expression, cell proliferation, cell
migration, cell death, immune pathways, and angiogenesis creates
a sum of sudden temporal changes in the microenvironment,
forcing the tumor to counter by expending energy (expend to
defend) and tipping the balance in favor of chemosensitivity (25).
Drug-Resistant Traits are Energetically
Expensive
Dr. Robert Gatenby, a practitioner of mathematical medicine,
characterizes the induction of resistance to cytotoxicity as an
energy intensive process, requiringATP expenditure to upregulate
xenobiotic metabolism, DNA repair, and inactivation of cell death
pathways (26). He postulates that treatment failure in oncology is,
for themost part, an iatrogenic phenomenon, caused by overtreat-
ment. In other words, the standard supra-inhibitory, maximally
tolerated dose (MTD)model, paradoxically facilitates the survival
of resistant clones.
It is well established that tumors are heterogeneous (27).
Within that heterogeneity, drug-intolerant cells are outcom-
peted by drug-sensitive variants for resources within the tissue
microenvironment. The acquisition of a refractory phenotype
is energetically expensive and inefficient (28). However, under
the selection pressure of MTD chemo- or radiotherapy (29),
resistant clones opportunistically replace the sensitive cells erad-
icated during treatment. By contrast, if chemosensitive cells are
not displaced, they impair the colonization and dissemination of
resistant populations. An analogous situation occurs in particular
body niches – skin, vagina, GU (genitourinary), and GI (gastroin-
testinal) tracts – where the microbial flora normally limits the
adherence of exogenous pathogens or indigenous opportunistic
commensals (30) unless antibiotic administration perturbs the
ecological balance.
For this reason, Gatenby proposes a non-MTDparadigm called
adaptive therapy (28), which preserves the viability and the pri-
macy of the drug-sensitive cells through continuous adjustment
of lower dose chemo over less frequent intervals to maintain a
mathematically defined target tumor burden. Proof-of-principle
studies have been completed in tumor bearingmice but no human
data are available. Similar sensitization/resensitization strategies,
which attempt to achieve a stable population of chemotherapy-
sensitive cells that suppress the growth of resistant populations,
include treatment holidays, metronomic dosing, OPTIMOX (31,
32), and COIN-like (33) intermittent treatment, and hypomethy-
lating agents.
The Epigenetic Landscape and
Retreatment After Drug Holidays
Waddington originally proposed the phrase “epigenetic land-
scape” as a metaphor to describe the process of biological devel-
opment (34, 35). Huang (36) and other computational biologists
have adopted the Waddington metaphor to represent movement
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FIGURE 1 | A diagram conceptualizing Waddington’s epigenetic
landscape. Drug resistance is at an energy maxima (peak), which tends to
arrive spontaneously at an energy minima (trough).
on a “rugged” energy landscape composed of high energy crests
and low energy troughs. The kinetic consequence of the rugged
energy landscape, according to Huang, is that “cells placed on
top of a mountain top or at a ‘watershed’ in the epigenetic land-
scape will roll down into just the few distinct valleys accessible to
them, driving the spontaneous separation into discrete fates” (37)
(Figure 1).
If the energy landscape metaphor is applied to the chemore-
sistant phenotype in oncology, and the crest of the hill is a
drug-resistant state, which is energetically unfavorable, requiring
ATP-consuming transcription and translation of proteins essen-
tial for resistance and/or xenobiotic elimination, then in the
absence of treatment the cancer cell, like a ball rolling down-
hill, may spontaneously proceed to the “low energy state” (37)
associated with drug sensitivity.
For this reason, the introduction of treatment holidays, during
which treatment is suspended for defined periods, may induce
reversion to the lowest energy or wild-type baseline drug-sensitive
state. Anecdotal cases of resensitization to epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
been reported in non-small cell lung cancer (NSCLC) patients
(38, 39) and genitourinary cancers after temporary treatment
interruption “with reported clinical benefits and good tolerability
when sequencing back to first-line therapy” (40). Re-treatment
responses have also been documented for standard cytotoxic
agents (41), which suggest that drug resistance is inherently unsta-
ble or metastable, and fades away after selection pressures are
removed. Sharma et al. and Knoechel et al. implicate the presence
of a subpopulation of drug-tolerant “persister cells,” transiently
refractory to killing, that stochastically develop resistance through
epigenetic mechanisms, and in particular, chromatin modifica-
tion, as a kind of “bet-hedging strategy” to generate pheno-
typic diversity and thereby maximize survival in an uncertain,
fluctuating environment without the need to activate energet-
ically intensive stress response pathways; consequently, similar
to bacterial cells, when the treatment pressure disappears, so
does resistance, which is facultative and reversible because it is
epigenetically rather than genetically acquired. This differentiates
persister cells, which arise from differential gene expression, from
resistant mutants that exhibit stable, irreversible, and heritable
drug insensitivity. (42, 43) However, these “passive” resensitiza-
tion events, which may correlate with the disappearance of the
persistence state during a treatment holiday, are welcome but one-
off exceptions to the general rule in oncology that chemoresistance
is inviolate.
Another “narrow” one-time exemption to the no resen-
sitization rule is the 2004 pivotal BOND (Bowel Oncology
and Cetuximab ANtiboDy) trial that served as the basis of
FDA (US Food and Drug Administration) approval for Cetux-
imab (Erbitux®), the anti-EGFR monoclonal antibody. In this
trial, where metastatic colorectal cancer (mCRC) patients previ-
ously treated with irinotecan-based regimens were randomized
to cetuximab plus irinotecan or cetuximab alone, the overall
response rate (RR) and median overall survival (OS) for the com-
bination armof cetuximab+ irinotecanwere 23% and 8.6months,
respectively, vs. 11% and 6.9months for cetuximab alone, respec-
tively, which provided support for resensitization (44).
These cetuximab resensitization results lack generalizability to
a wider population of irinotecan-refractory cancers, since one
of the underlying mechanisms of irinotecan resistance is EGFR
upregulation (45). As evidence for the stability of this resistance
that emerges during therapy, Wadlow et al. published a phase
II trial of 20 patients with cetuximab-refractory mCRC treated
subsequently with human anti-EGFR monoclonal antibody, pan-
itumumab (Vectibix®), where no responses were observed (46).
However, a general rule of inversion does occur in the context
of epigenetic priming, which potentially leads to resensitization
across multiple tumor types, discussed below.
Metronomic Dosing
Hanahan, Bergers, and Bergsland described metronomic
chemotherapy thusly: “Less is more, regularly” (47). In contrast
to supratherapeutic MTD bolus chemotherapy, metronomic
administration involves regularly timed (like the beat of a
metronome) low-dose conventional chemotherapy to avoid both
myelosuppression and drug resistance (48). If the drug-resistant
state imposes an energetic burden, making resistant cells inferior
competitors to their drug-sensitive counterparts, as Gatenby has
claimed, then ultra-low doses of chemotherapy may delay but
not prevent (49) the onset of treatment resistance. Nevertheless,
Hanfeldt et al. (50) have described repeated “resensitization” to
chemotherapy after a transient refractory phase with metronomic
dosing, which appears to support the “less is more, regularly”
slogan.
Interrupted Dosing
In routine clinical practice, cancer patients are exposed to sequen-
tial and multiple lines of continuous systemic therapy, with a
switch to the next line mandated by objective evidence of radi-
ologic/symptomatic progression or intolerable toxicity, and only
rare instances of rechallenge with the same agent. However, the
frequency of drug holidays, where treatment is temporarily dis-
continued, in an attempt to reduce chronic cumulative toxicities
and restore partial drug sensitivity, suggests that intermittent
administration may be a preferable treatment strategy to contin-
uous dosing.
Three clinical trials in mCRC, OPTIMOX-1, COIN, and
AIO KRK 0207 have investigated whether it is safe to intro-
duce chemotherapy-free periods without impacting OS. Each of
these trials is briefly discussed below from the perspective of
resensitization.
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The OPTIMOX-1 trial, intended to address cumulative neu-
rotoxicity with oxaliplatin-based therapy, demonstrated that the
interrupted “stop and go” administration of FOLFOX4 treatment
for 6 cycles followed by maintenance 5-FU/LV only, with no
oxaliplatin for 12 cycles, and reintroduction FOLFOX4 for 6 cycles
is as effective as continuous FOLFOX7 until disease progres-
sion or toxicity (51) and results in less neurotoxicity. However,
resensitization was not demonstrated.
The Phase III COIN trial compared continuous oxaliplatin and
fluoropyrimidine vs. 3months of oxaliplatin and fluoropyrimi-
dine followed by a preplanned chemotherapy holiday until disease
progression and then treatment reinduction. Resensitization was
not demonstrated. Survival of about 6weeks was noted in the
intermittent arm, but this still did not support resensitization.
AIO KRK 0207 investigated the effect of a 24-week standard
induction with FOLFOX+ bevacizumab, no continuation of ther-
apy or continuationwith bevacizumab alone, followed by reinduc-
tion after progression. This study also did not demonstrate resen-
sitization, since time to failure of strategy, a composite measure of
progression-free survival, was worse in the no treatment arm.
The absence of resensitization on the intermittent or no treat-
ment arms may be related to protocol non-adherence since in
all three trials the reinduction rate was low, possibly due to the
toxicity of treatment (52, 53).
DNA Methyltransferase Inhibitors
Similar to the “less is more” principle that characterizes metro-
nomic dosing (54). the azanucleotides, AZA, and DAC are more
effective at lower “epigenetically targeted” concentrations due to
inhibition of DNMTs (55) and global hypomethylation, which
leads to re-expression of silenced tumor suppressor genes.
At these epigenetically targeted doses, systematic observa-
tions of resensitization to previously failed therapies have been
reported most notably in platinum-refractory ovarian cancer. The
word systematic is italicized to highlight the difference between
active and spontaneous resensitization events. In the former,
hypomethylating agents elicit a predictable and purposeful pattern
of altered gene expression, while spontaneous resensitization (e.g.,
from pulsed or intermittent treatment schedules) occurs incon-
sistently and unpredictably. Reversion to drug sensitivity may
happen eventually; however, due to randomness, it is evidently
impossible to predict when (or if) that event will occur, which ren-
ders spontaneous resensitization of an unreliable strategy. The dif-
ferent examples of non-epigenetic resensitization are represented
below (Figure 2).
Clinical Trials that Feature
Epi-Resensitization
Ovarian cancer, hepatocellular carcinoma (HCC), colorectal can-
cer, NSCLC, and cholangiocarcinoma are some of the tumor types
where an episensitization strategy has already been explored or is
currently under investigation.
(1) Ovarian cancer
Standard first-line therapy for advanced ovarian cancer con-
sists of a combination of a platinum and a taxane usually
carboplatin and paclitaxel administered intravenously every
3weeks for six cycles (56). Nevertheless, while most tumors
are initially responsive, patients inevitably develop resistance
to platinum and all other therapies, at which point their
5-year survival rate drops to only 20% (57) because recur-
rent disease is almost always incurable. Decision-making for
second-line treatment is based on a three category clinical
classification, platinum-refractory, platinum-resistant, and
platinum-responsive, defined by the time interval of relapse
after the end of first-line platinum-containing chemother-
apy regimen (58): platinum-refractory tumors progress dur-
ing platinum-based therapy and have the worst prognosis;
platinum-resistant disease recurs <6months after platinum-
based therapy; platinum-sensitive disease recurs more than
6months from the completion of the initial platinum-based
therapy (59). With the exception of platinum-sensitive dis-
ease, which may benefit from retreatment with either cis-
platin or carboplatin, secondary response to platinum-based
agents for resistant/refractory patients (60) is extremely
unlikely.
(a) Phase II clinical trial of DAC and carboplatin in
platinum-refractory/resistant ovarian cancer.
Matei et al. (61) tested the activity of AZA and
carboplatin in 17 patients with heavily pretreated
and platinum-resistant ovarian cancer in a phase
II clinical trial. RR and progression free survival
were 35% and 10.2months, respectively, indicative of
epi-resensitization and clinical benefit since objective
responses are not only uniformly short-lived but <10%
in this patient population (62).
(b) Phase I/II study of 5-azacytidine and carboplatin
platinum-refractory/resistant ovarian cancer.
In this similar trial, Fu et al. (63) administered AZA
75mg/m2 subcutaneously daily for 5 days to reverse
resistance to carboplatin in patients with platinum-
resistant or refractory ovarian cancer. The fact that the
overall RR was 13.8% (4 of 29 patients) with 1 patient
achieving a complete response and 3 patients achieving
a partial response (PR); the disease control rate [PR
plus stable disease (SD)] was 45% (13 of 29 evaluable
patients) and the median OS was 14months, is also
indicative of epi-resensitization since in this subset of
patients the probability of benefit with carboplatin is
unlikely.
(2) Advanced HCC.
The multikinase inhibitor, sorafenib (64), is the first-line
standard of care in HCC patients, however, RRs are low,
resistance to therapy inevitably develops, and no approved
therapies are available in the second-line setting. Resminos-
tat is an oral pan-HDAC inhibitor.
(a) Phase II SHELTER study of resminostat+ sorafenib vs.
resminostat alone in second-line HCC after sorafenib
progression in first-line treatment.
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FIGURE 2 | A diagram showing four different dosing strategies.
(1) MTD dosing – maximal doses with maximal resistance.
(2) Metronomic dosing – less is more regularly. (3) Intermittent dosing
–start and stop dosing theoretically leads to less resistance than
continuous dosing. (4) Adaptive therapy – dosing level and frequency
adapted for tumor stability.
The OS is reportedly 8.1months in the resminostat+
sorafenib arm vs. 4.1months for resminostat alone (65).
The expected OS in second-line HCC, in other words,
after patients progress on sorafenib is 5.2months,
resulting in a modest survival benefit of about
3months in the combination sorafenib/resminostat
epi-resensitization arm.
(3) mCRC.
Unlike the fairly rigid dependence on serial lines of treatment
in the majority of tumor types, a flexible “continuum of
care” (66)model characterizes themanagement ofmetastatic
colon cancer. Continuum of care involves strategic pairing of
approved chemotherapy agents, including 5-FU, irinotecan,
bevacizumab, capecitabine, panitumumab, cetuximab, and
regorafenib in any order (67); however, rechallenge with
formerly failed therapies is typically not attempted since
the risks likely outweigh the potential benefits. The recently
approved agent, regorafenib, is recommended for third-line
therapy in patients pretreated with fluoropyrimidines, oxali-
platin, irinotecan, bevacizumab, or anti-EGFR antibodies.
The epigenetics of colorectal cancer has been reviewed
extensively and preclinical studies suggest that epigenetic
therapies like vorinostat may reverse chemoresistance in
colorectal tumors (68).
In addition, preliminary clinical evidence demonstrates that
the epigenetic agent, RRx-001, a systemically non-toxic
intravenous agent, sourced from the aerospace indus-
try, reverses chemoresistance to irinotecan in a ran-
domized Phase II mCRC trial vs. regorafenib with the
acronym ROCKET for RRx-001 in COlon Cancer TaKen To
Extend Time. This trial systematically explores a switch-at-
progression strategy of RRx-001 priming followed by irinote-
can, RRx-001, then irinotecan, etc.
(a) Phase II (ROCKET) study of weekly RRx-001 random-
ized against current third treatment, regorafenib, and
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FIGURE 3 | A diagram depicting the ROCKET trial design. Patients with
mCRC are randomized to RRx-001 or regorafenib. On progression, both
arms are rechallenged with irinotecan-based therapies, if clinically
appropriate. The primary endpoint is OS. Another endpoint is PFS measured
as the sum of PFS (RRx-001 or regorafenib)+PFS (irinotecan therapies).
followed by irinotecan-based therapies on progression
(Figure 3).
This recently initiated Phase II two-part clinical trial
consists of a priming phase and a successive cytotoxic
chemotherapy phase. Previously treated irinotecan-
refractory third/fourth-line colorectal cancer patients
are randomized to RRx-001 or regorafenib administered
until progression, intolerable toxicity, or patient choice.
Per protocol irinotecan-based therapy is reintroduced
on both arms, if clinically appropriate. In addition, the
RRx-001 patients, if appropriate, are allowed to con-
tinue on trial in a repetitive retreatment loop, a circular
dichotomization that alternates between RRx-001 and
irinotecan-based therapies (Figure 4).
Epi-resensitization is defined by any of the following (1)
a drop in carcinoembryonic antigen (CEA) levels; (2)
clinical and/or radiologic stability; (3) prolonged clinical
benefit on therapy leading to increase OS. The primary
endpoint is OS.
To date, six out of eight RRx-001 patients have been suc-
cessfully rechallenged with irinotecan-based therapies
after completion of the first priming phase of the study.
These six patients met criteria for resensitization with
one or more of the following: a (1) decline in the tumor-
associatedmarker carcinoembryonic antigen (CEA); (2)
improvement in clinical performance status; and/or (3)
PR/SD on positron emission tomography (PET) or com-
puter tomography (CT). One of the patients demon-
strated ametabolic PR on PET and SDonCT. In contrast
to the RRx-001-treated arm, the regorafenib patients all
clinically deteriorated and have been unable to start any
subsequent chemotherapy. The primary hypothesis is
FIGURE 4 | A diagram depicting the RRx-001 resensitization loop. In
the ROCKET trial, RRx-001 patients are shuttled between RRx-001 and
FOLFIRI in an iterative retreatment loop.
that the successful reintroduction of previously effective
therapies with subsequent regression or prolonged stabi-
lization of disease will improve long-term survival rates
compared to the regorafenib control arm.
These early examples suggest that RRx-001 epige-
netically primes tumors to re-respond to irinotecan-
based therapies. The prolonged nature of resensitiza-
tion to irinotecan-based therapies are akin to those
of treatment-naïve mCRC patients, who have never
been previously exposed to chemotherapy, since the
median PFS in second-line metastatic colorectal therapy
is 4.5months (69).
(b) Phase I Study of SGI-110 combined with irinotecan
followed by a randomized phase II study of SGI-110
combined with irinotecan vs. regorafenib in previously
treated mCRC patients.
In this recently initiated two-part combination Phase I
clinical trial, the combination of the second generation
DNMT inhibitor, SGI-110, and irinotecan is compared
to the standard of care regorafenib in mCRC. No data
are available.
(4) NSCLC.
In patients with advanced or metastatic NSCLC, the median
survival is 10–12months. The current first-line chemother-
apy standard is one of a number of platinum-based doublets
followed in second line by treatment with the chemother-
apy agents docetaxel and pemetrexed, or treatment with
an oral EGFR antagonist, erlotinib. These patients have
limited treatment options (and poor outcomes) after pro-
gression in second-line. Retrospective analysis of third-line
chemotherapy shows RRs of only 2% andmedian survival of
4months (70).
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(a) Phase I/II clinical trial of combined epigenetic ther-
apy with AZA and entinostat in extensively pretreated
recurrent metastatic NSCLC.
This trial demonstrates tumor preconditioning or prim-
ing prior to subsequent therapies, which is consis-
tent with episensitization. Treatment with low-dose
AZA and entinostat by Juergens et al. (71) achieved a
favorable objective RR and survival benefits (>1 year
in approximately 20% of the patients and a median
OS of 6.4months), which exceeded historical controls
(48% expected survival after 6months). The favor-
able survival was attributed to an “unusually robust
response to subsequent cytotoxic therapies with which
the majority of patients were treated” (9). The sub-
sequent therapies in the NSCLC trial included peme-
trexed, docetaxel, erlotinib, anti-programed cell death
protein (PD-1) monoclonal antibodies, gemcitabine,
irinotecan/bevacizumab, and cisplatin, suggesting that
the combination of AZA and entinostat reversed the
multimodality resistance phenotype, thereby enhancing
susceptibility to a variety of subsequent chemotherapeu-
tic agents.
(b) Pilot Three-Arm Study (TRIPLE THREAT) of RRx-
001 administered in small cell lung cancer, NSCLC,
and extrapulmonary neuroendocrine tumors prior to re-
administration of platinum-based doublet regimens –
this trial is scheduled to start recruitment in Q1 2015.
(5) Cholangiocarcinoma
Cholangiocarcinoma is a rare, heterogeneous group of
tumors with an incidence that ranges from 1 to 3 per
100,000 in the United States (72). The majority of patients
who develop cholangiocarcinoma are incurable; palliative
gemcitabine plus platinum combination chemotherapy is
standard practice (73) as first-line treatment while the ben-
efits and feasibility of second-line salvage chemotherapy are
unclear and under investigation.
(a) Phase II (EPIC) trial of weekly RRx-001 adminis-
tered for 6weeks in second-line therapy prior to re-
administration of gemcitabine/cisplatin – this trial is
scheduled to start recruitment in 2015.
Discussion and Future Perspective
The traditional assumption in oncology that resistance is
inevitable, stable, and homogeneous, eventually leading to tumor
progression and death, with small chance for alleviation or
reprieve, generally prevents a retrial of previously effective
chemotherapy due to the risk of toxicity without benefit. Con-
trary to this prevailing view, the work of Huang and Gatenby,
in particular, cited earlier, demonstrates that acquired resistance,
energetically expensive to produce and maintain, is poten-
tially a context-dependent and -reversible process. As explained
by Gatenby, one-size-fits-all MTD-based treatment is fuel for
the evolution and emergence of resistance against multiple
FIGURE 5 | A diagram depicting the concept of proliferation-
resistance trade-offs. Tumors allocate finite resources toward proliferation
or resistance, depending on the presence or absence of specific stresses.
This process is referred to as the proliferation-resistance trade-off.
chemotherapies (74). Because cancer cells possess a finite pool
of resources, due to a decreased efficiency of energy metabolism
via glycolysis and thus ATP production, the possession of these
defense mechanisms is a metabolically costly trade-off that com-
promises proliferation (Figure 5); this negative impact on prolif-
eration is only supportable when the associated benefits outweigh
the costs. It is hypothesized that when the external selection pres-
sure is removed, the tumor will revert to baseline and adopt, on
balance, a drug-sensitive phenotype. However, it is unpredictable
if, when, and how quickly the cell will overcome phenotypic
inertia. Moreover, the very act of treatment elicits a Catch-22 of
resistance even after a chemotherapy-free interval.
The apparent solution to this paradoxical situation is epige-
netic modulation, because it globally modulates gene expression,
which disrupts the specialized fit between the cancer cell and its
microenvironment, forcing the tumor to recalibrate and reset at
the expense of de novo and acquired resistance. While reversal
of resistance may occur spontaneously during treatment inter-
ruption, resensitization is more reliably elicited with epigenetic
agents, which justifies the use of the term epi-resensitization.
In conclusion, episensitization has the potential to increase the
expectancy of survival from mere months to multiple years, as
resensitized patients iteratively loop between epigenetic agents
and formerly refractory treatments in consecutive cycles. The goal,
1 day, is to bend or hopefully even turn back the one-way arrow of
time and transform cancer from a terminal to a chronic disease.
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